1. Home
  2. BLBD vs MESO Comparison

BLBD vs MESO Comparison

Compare BLBD & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blue Bird Corporation

BLBD

Blue Bird Corporation

HOLD

Current Price

$47.85

Market Cap

1.7B

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$19.89

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLBD
MESO
Founded
1927
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Construction/Ag Equipment/Trucks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BLBD
MESO
Price
$47.85
$19.89
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$64.60
$24.00
AVG Volume (30 Days)
370.9K
218.0K
Earning Date
02-04-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
22.79
N/A
EPS
3.88
N/A
Revenue
$1,480,099,000.00
$17,198,000.00
Revenue This Year
$4.86
$576.59
Revenue Next Year
$3.41
$41.15
P/E Ratio
$12.13
N/A
Revenue Growth
9.87
191.39
52 Week Low
$30.04
$9.61
52 Week High
$61.95
$21.00

Technical Indicators

Market Signals
Indicator
BLBD
MESO
Relative Strength Index (RSI) 39.98 65.03
Support Level $46.44 $17.90
Resistance Level $47.89 $18.73
Average True Range (ATR) 1.34 0.55
MACD -0.29 -0.03
Stochastic Oscillator 25.33 79.92

Price Performance

Historical Comparison
BLBD
MESO

About BLBD Blue Bird Corporation

Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: